| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2850954 | American Heart Journal | 2008 | 9 Pages |
Abstract
In patients paced for SND and suffering from AT, class IC AADs proved not to be inferior to amiodarone in terms of the primary composite end point described or end points which were differently composed of mortality, efficacy, or AAD side effects. The AADs studied also showed similar results in terms of symptoms, quality of life, and freedom from AT recurrences.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Michele MD, FESC, Salvatore MD, Serafino MD, Giacomo MD, Guglielmo MD, Nicolò MD, Andrea MD, Orazio MD, Francesco MD, Ludovico MD, Andrea PhD, Giuseppe MD, on behalf of PITAGORA Study Investigators on behalf of PITAGORA Study Investigators,